DeHeng Advised bioGenous on Raising Nearly RMB 100 Million in Series A Financing

2023-01-06

Recently bioGenous Technologies (Suzhou) Co., Ltd. announced the completion of Series A financing of nearly RMB 100 million. The lead investor was CMG SDIC Capital, in addition to investment in excess of the proportion from the existing shareholder Marathon Venture Partners. The money raised will be used to improve the company’s world-leading organoid CDMO and CRO processes and technologies, build and put commercial production bases into operation at an earlier date, and expand overseas markets.

The financing will enable bioGenous to continue to strengthen its platform capacity building for multi-lineage and multi-cancer organoid construction, gene manipulation, drug discovery and efficacy evaluation, and experimental animal transplant, comprehensively increase its production capacity, and lead the multi-field model revolution in biomedicine. The financing will also support bioGenous to explore overseas markets, move faster to develop “end-to-end, global” proprietary organoid products and services, and promote the application of organoids as an emerging technology in the pharmaceutical industry.

As the legal counsel, the DeHeng team, with primary support from Shanghai Office partners Zhang Lei, Fang Wen, Shang Shuaili and Xiao Jun, completed structural adjustment, document review, project negotiation, delivery follow-up, etc. on behalf of bioGenous. They worked closely together to get the job done professionally and efficiently.